Bone scanning and photon absorptiometry in metabolic bone disease.
Bone scan imaging with the current bone-seeking radiopharmaceuticals, the technetium-99m labelled diphosphonates, provides a functional display of skeletal metabolism and has dramatically improved our ability to investigate skeletal pathology. While the role of bone scanning in metastatic disease was recognized early, and welcomed by oncologists and other specialists alike, in the field of metabolic bone disease the realization of its potential value has been slower, with perhaps more reluctant acceptance. Nevertheless, the skeleton remains an extremely difficult organ to investigate, and a familiarity with bone scanning should be an essential part of the investigational armamentarium for anyone with an interest in the metabolic bone disorders. The measurement of bone mineral by photon absorptiometry is a relatively new technique, which is rapidly gaining acceptance. The ability to accurately detect and quantify changes in bone mass is potentially of considerable value in the diagnosis and management of osteoporosis. The technique provides us with an extremely important and powerful research tool but, at the present time, its role in clinical practice has yet to be established.
D000818:Animals; D001851:Bone Diseases, Metabolic / Q000000981:diagnostic imaging* / Q000378:metabolism; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000378:metabolism; D004164:Diphosphonates / Q000493:pharmacokinetics; D006801:Humans; D008903:Minerals / Q000378:metabolism; D011877:Radionuclide Imaging; D013667:Technetium / Q000493:pharmacokinetics; D017556:Technetium Compounds
D004164:Diphosphonates; D008903:Minerals; D017556:Technetium Compounds; D013667:Technetium; C029045:technetium Tc 99m diphosphonate